Sorrento Therapeutics (SRNE) Says Financial Statements Should no Longer be Relied Upon
Tweet Send to a Friend
Sorrento Therapeutics (NASDAQ: SRNE) disclosed in an SEC filing:On February 26, 2018, the Audit Committee of the Board of Directors ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
